AI

In 18 months, vaccine research advanced AI in medicine by five to seven years. That’s cause for optimism — and investment — in the digital transformation of clinical development says Jeff Elton, CEO of Concerto HealthAI, who has extensive experience in this sector, and shares his insight with DDW.  In the full interview, which can be downloaded and […]

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks with Dr Orloff about his career and the future of […]

IBM Research and Arctoris are investigating the application of AI and automation to accelerate closed loop molecule discovery.   IBM Research has developed RXN for Chemistry, an online platform leveraging Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES (Simplified Molecular Input Line Entry System), the system is designed to perform reaction predictions […]

Microbiome experts from Microba Life Sciences will discuss the next phase of discovery from the microbiome to a global audience via a series of webinars on September 15 (PST 10am-12pm | EST 1-3pm | CET 7pm).  Professor Gene Tyson, Associate Professor Lutz Krause and Dr Alena Pribyl will discuss how advancements in metagenomic analysis techniques are revealing novel biomarkers and relationships […]

Exscientia has announced that Bristol Myers Squibb has elected to in-license its immune-modulating drug candidate. Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. A significant expansion of the relationship was announced earlier this year.  The in-licensed candidate targets a critical immunological kinase that historically has proven […]

Digital Science has launched a new version of its Dimensions platform – Dimensions Life Sciences & Chemistry – focused on life sciences and chemistry research activities.   Dimensions L&C analyses more than 120 million scientific publications, millions of patents, grants and clinical trial documents. It applies semantic text analysis tools and ontologies, providing powerful up-to-date discovery functionality previously […]

Insilico Medicine has announced today that its AI-powered drug discovery platform has delivered a preclinical candidate for kidney fibrosis. The preclinical candidate has desirable pharmacological properties and pharmacokinetic profile and has demonstrated highly promising results in in-vitro and in-vivo preclinical studies. Insilico Medicine is working to advance this program to clinical trials and plans to […]

Exscientia and GT Apeiron Therapeutics have entered an R&D collaboration. Exscientia’s AI expertise will  be used to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. This collaboration follows the design of multiple selective CDK7 compounds. The […]

The Covid-19 pandemic has given businesses opportunity to implement technology-fuelled changes to the way they operate. AI and big data/analytics have been identified by healthcare industry professionals as the top technologies that will transform pharmaceutical drug discovery and development processes, as well as marketing and sales, according to a survey by GlobalData, a data and […]

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the Covid-19 Therapeutics Accelerator initiative, to progress a new class of Covid-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform to design a novel class […]